Effects of exogenous Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during hyperglycaemic clamp experiments in healthy volunteers.

开始日期2013-09-06

申办/合作机构-

ACTRN12610000185066

/ Completed临床2期IIT

The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients with pre-existing type-2 diabetes during small intestinal feeding

开始日期2009-07-01

申办/合作机构-

ACTRN12609000093280

/ Completed临床2期IIT

The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients during small intestinal feeding

开始日期2008-07-01

申办/合作机构-

100 项与 Glucagon-like peptide-1 ( MannKind Corporation) 相关的临床结果

登录后查看更多信息

100 项与 Glucagon-like peptide-1 ( MannKind Corporation) 相关的转化医学

登录后查看更多信息

100 项与 Glucagon-like peptide-1 ( MannKind Corporation) 相关的专利（医药）

登录后查看更多信息

317

项与 Glucagon-like peptide-1 ( MannKind Corporation) 相关的文献（医药）

2026-03-03·LANGMUIR

Self-Assembly of a Therapeutic Peptide Surfactant: A Small-Angle X-ray Scattering Study

Article

作者: Sigfridsson, Kalle ; Bergström, L. Magnus ; Brunzell, Ellen

Amphiphilic compounds are important in many fields including pharmaceutical processes and development. Synthetic surfactants are often toxic to biological systems and frequently display poor biodegradability. Biosurfactants, such as lipopeptides and bile salts, on the other hand, can offer superior properties with regard to toxicity, biodegradability, and efficiency. Lipidated peptides are also gaining interest as therapeutic agents, as they can offer enhanced pharmacokinetic properties, compared with native peptides. The amphiphilic nature of lipidated peptides suggests that they may self-assemble into micellar structures, which can influence formulation stability and biological performance. Understanding the aggregation behavior of lipidated peptides is thus important for identifying and avoiding stability issues that could affect drug efficacy and safety. Structural characterization of self-assembled aggregates provides insight into aggregation mechanisms, which is valuable for identifying potential challenges during the production, storage, and administration of pharmaceutical peptides. By using small-angle X-ray scattering (SAXS), we have investigated the size and morphology of aggregates formed by MEDI7219, a bis-lipidated glucagon-like peptide-1 (GLP-1) analogue, in various aqueous solutions. We demonstrate that the lipopeptide MEDI7219 behaves as a surfactant with high spontaneous curvature that forms small micelles with a clear core-and-shell structure in aqueous solvents. The aggregation numbers of the micelles vary in the range of 5-8 and are found to be surprisingly insensitive to environmental conditions such as type of electrolyte and tonicity modifier, different buffers, and temperature, while exhibiting very low critical micelle concentrations (cmc).

2026-01-12·JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5 × FAD mice

Article

作者: Qi, Liqin ; Liu, Xiaohong ; Chen, Zhou ; Liu, Libin ; Liu, Xiaoying ; Lin, Lijing ; Zheng, Jiaping

Abstract:

Background:

Alzheimer’s disease (AD) is a degenerative disease of the central nervous system characterized by progressive memory decline. The increasing prevalence of AD has attracted considerable attention globally. The glucagon-like peptide-1 analog, liraglutide, a drug widely used in the treatment of type 2 diabetes, has shown promising neuroprotective effects in AD, including enhancing neuronal survival, reducing amyloid beta protein accumulation, improving synaptic plasticity, and reducing tau protein hyperphosphorylation. However, its potential impact on cognitive function remains unclear.

Methods:

We evaluated the effects of liraglutide (25 nmol/day for 8 weeks) on the cognitive ability of 12-month-old 5 × familial AD (FAD) mice. The Morris water maze test was used to evaluate the spatial learning ability of mice. Histological evaluations were performed by Nissl staining and transmission electron microscopy. Neuroinflammation was detected by double immunofluorescence staining and enzyme-linked immunosorbent assay. Protein expression in the cortex and hippocampus was detected by immunohistochemistry and Western blotting.

Results:

The spatial cognitive ability improved in 5 × FAD mice after liraglutide administration and was associated with an increased number of pyramidal cells in the cortex and hippocampus. Liraglutide also alleviated ultrastructural changes in the chemical synapses and reduced both local and systemic inflammation in AD mice. Furthermore, liraglutide reduced amyloid β protein expression, which may be associated with the regulation of nuclear factor kappa B/beta-secretase 1 pathways in AD mice.

Conclusions:

The potential of liraglutide to improve cognitive function in AD mice offers an effective pharmacological approach for treating neurodegenerative diseases.

2026-01-01·NATURE MEDICINE

The expanding landscape of GLP-1 medicines

Review

作者: Drucker, Daniel J

Glucagon-like peptide-1 medicines are being prescribed to growing numbers of patients worldwide, for type 2 diabetes, obesity and associated comorbidities, including cardiovascular disease, peripheral artery disease and obstructive sleep apnea, and are revolutionizing public health strategies for these conditions. These medicines improve health through reduction of blood glucose and body weight, by attenuation of inflammation and via direct activation of receptors in target tissues. New, more effective molecules with optimized pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes. Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease. Here we highlight data informing the safety, efficacy, and potential utility of new and emerging glucagon-like peptide-1 medicines. We outline new mechanistic concepts, future therapeutic opportunities, potential for differentiation from currently available medicines and areas of uncertainty requiring additional investigation.

项与 Glucagon-like peptide-1 ( MannKind Corporation) 相关的新闻（医药）

2026-03-09

·drugs

GLP-1 Receptor Agonist Use Linked to Reduced Risks for Substance Use Disorder

MONDAY, March 9, 2026 -- The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs), according to a study published online March 4 in The BMJ . Miao Cai, Ph.D., from the VA Saint Louis Health Care System, and colleagues examined whether initiation of GLP-1 receptor agonists is associated with a reduced risk for incident SUDs in people with no history of SUD (protocol 1) or with a reduced risk for SUD-related adverse clinical outcomes among people with a preexisting SUD (protocol 2). Seven trials were included for each incident SUD outcome (protocol 1), and one trial was included for adverse outcomes in people with preexisting SUD (protocol 2). The primary trial of protocol 1 included 524,817 initiators of GLP-1 receptor agonists or sodium-glucose cotransporter-2 (SGLT-2) inhibitors (124,001 and 400,816, respectively). Protocol 2 included 16,768 GLP-1 receptor agonist initiators and 64,849 SGLT-2 inhibitor initiators. The researchers found that GLP-1 receptor agonist initiation was associated with a reduced risk for disorders related to alcohol use, cannabis use, cocaine use, nicotine use, opioid use, and other SUDs compared with initiation of SGLT-2 inhibitors (hazard ratios, 0.82, 0.86, 0.80, 0.80, 0.75, and 0.87, respectively) and with a reduced risk for the composite outcome of all incident SUDs (hazard ratio, 0.86). GLP-1 receptor agonist initiation was associated with a reduced risk for SUD-related emergency department visits, SUD-related hospital admissions, SUD-related mortality, drug overdose, and suicidal ideation or attempt (hazard ratios, 0.69, 0.74, 0.50, 0.61, and 0.75, respectively) among people with preexisting SUDs. "Our results show that GLP1 receptor agonist-related agonism may prevent addiction phenotypes across all major drug classes," the authors write. One author disclosed ties to Pfizer. Abstract/Full Text Editorial

临床结果临床2期

2026-01-05

·drugs

Incretin Receptor Agonists Tied to Better Outcomes in Adults With Obesity, T2DM, Obstructive Sleep Apnea

MONDAY, Jan. 5, 2026 -- Initiation of incretin receptor agonists (IRAs) is associated with lower continuous positive airway pressure (CPAP) use, hospitalization, and mortality among adults with obesity, type 2 diabetes, and obstructive sleep apnea (OSA), according to a research letter published online Dec. 22 in JAMA Network Open . Huilin Tang, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues evaluated the effectiveness of IRA use in routine care among adults with obesity, type 2 diabetes, and OSA. The analysis included 36,981 matched pairs of adult IRA and sodium-glucose cotransporter-2 inhibitor (SGLT2i) users with obesity, diabetes, and OSA, identified from the TriNetX research network. The researchers found that during a mean follow-up of 332.2 days, 6.6 percent of IRA and 7.2 percent of SGLT2i users received CPAP therapy. IRA use was associated with decreased risks for CPAP use (hazard ratio [HR], 0.92), all-cause mortality (HR, 0.68), and hospitalization (HR, 0.90) compared with SGLT2i use. Results generally were consistent across subgroups, although no association was found for CPAP use in women or older adults. There were decreased risks for CPAP use and mortality for tirzepatide and glucagon-like peptide-1 (GLP-1) receptor agonists compared with SGLT2is, with tirzepatide showing greater decreases than GLP-1 receptor agonists. "The modest effect size for IRAs suggests limited clinical relevance for CPAP use alone, but reductions in mortality and hospitalization support broader cardiometabolic benefits," the authors write. Two authors disclosed financial ties to the pharmaceutical industry. Abstract/Full Text

临床结果

2025-12-09

·PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

Novo Nordisk has presented new findings from its phase 3 Evoke and Evoke+ trials on using semaglutide as part of Alzheimer’s disease (AD) treatment. The trials did not meet their primary endpoints; however, they still highlighted important biomarker findings. Semaglutide demonstrated reductions of up to 10% in biomarkers linked to AD and neuroinflammation that, despite not being a large enough change to have clinical impact, is still a notable result. Semaglutide is a glucagon-like peptide-1 (GLP-1) drug currently used in the treatment of type 2 diabetes, and as a weight management medication. Research into other possible indications of GLP-1 drugs is ongoing. There is high unmet medical need for treatment in AD, a progressive neurodegenerative disease which currently has no cure. The Alzheimer’s Drug Discovery Foundation (ADDF) made early investments in the science that led to the Evoke trials, stressing that the full pathophysiology of AD needs to be addressed in order to discover possible treatment. From 2011, the ADDF provided nearly $1m to Paul Edison’s phase 2 study of liraglutide, another injectable GLP-1 drug. Edison, a professor of neuroscience in the Faculty of Medicine at Imperial College London, said: “The metabolic pathway remains a compelling area of investigation, and we will continue to pursue rigorous studies to determine how therapies targeting these mechanisms can be optimised and combined to achieve greater impact for patients.” Founded in 1998, the ADDF is a foundation focused on accelerating the discovery and development of drugs to treat AD. It is the only public charity with this focus, and its funding has assisted in bringing to market the first Alzheimer’s PET scan (Amyvid) and blood test (PrecivityAD). “With more than 70% of the Alzheimer’s drug pipeline now focused on non-amyloid targets, the field is moving steadily toward an era of precision medicine and combination therapies,” said Howard Fillit, co-founder and chief science officer of the ADDF. “The Evoke trials are an important part of this progress, demonstrating how large-scale studies of novel pathways can deepen our understanding of Alzheimer’s biology.”